CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04037566 |
|
Recruitment Status :
Recruiting
First Posted : July 30, 2019
Last Update Posted : July 30, 2019
|
Sponsor:
Xijing Hospital
Collaborator:
Xi'An Yufan Biotechnology Co.,Ltd
Information provided by (Responsible Party):
Gao Guangxun, Xijing Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 2021 |
| Estimated Study Completion Date : | August 2024 |